Sanofi's ($SNY) Merial has released what the animal health company boasts as the first nonadjuvanted feline rabies vaccine with a three-year lifespan. While other similar products have been associated with causing vaccine-related fibrosarcoma, a rare disease, Merial claims the first-of-its-kind vaccine is safe. "Veterinarians now no longer have to choose between a multiyear adjuvanted rabies vaccine and an annual nonadjuvanted rabies vaccine for clients who do not reliably return to the clinic annually," the company wrote in a statement. Article